Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab added to LMB chemotherapy for high-risk childhood B-cell lymphoma or B-ALL
NL-OMON21840Phase 3Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in mature B-cell lymphoma, acute lymphoblastic leukemia (ALL) and primary mediastinal large B-cell lymphoma (PMBCL) (3 arms), sponsored by Gustave Roussy. Primary endpoint: Event-free survival. Planned start Dec 2011; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
mature B-cell lymphomaacute lymphoblastic leukemia (ALL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NL-OMON21840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21840.